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Abstract Meningiomas represent the most common primary
brain tumor and comprise 3 World Health Organization
(WHO) grades, the most frequent being WHO grade I
(90 %). Surgery is mandatory to establish the diagnosis and
to remove the tumor; however, complete resection can be
achieved in only <50 % of patients. Depending on the extent
of resection, tumor location and the WHO grade radiation
therapy can be applied. The issue of systemic treatment such
as chemotherapy or targeted therapy (eg, somatostatin recep-
tors, antiangiogenic agents) is yet not solved, particularly as
current data are derived from small uncontrolled series in
patients with long-standing disease and after several pretreat-
ments. A more thorough understanding of molecular genetics,
signaling pathways and prognostic factors in meningiomas
should lead to the design of studies which stratify according
to these factors. These studies have to be conducted in newly
diagnosed patients after incomplete resection and in tumors of
WHO grade II and III.
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Introduction
Meningiomas represent the most common intracranial extra-
axial neoplasia. In adults they account for approximately
30 % of central nervous system (CNS) tumors, whereas they
are rare in children and adolescents (0.4 %–4.6 %) [1••]. The
incidence increases with age and shows a remarkable pre-
dominance in females particularly in the 3rd to 6th decade
(female:male ratio 2:1) [2]. Meningiomas are frequently
detected by chance (‘incidentaloma’) and show no or only
minor growth particularly when tumor calcification is pres-
ent in the elderly [3]. They are found in up to 3 % of autopsy
reports [4] in patients over 60 years old. Meningiomas can
arise anywhere within the CNS, and multiple manifestations
are not uncommon. Distant metastasis is very rare. The
spontaneous rate of tumor growth varies [5]. Considering
the aging population, improvements in treatment safety as
well as the availability and performance of imaging, we are
expecting an increased incidence in future daily practice [3].
This fact requires interdisciplinary networks in specialized
centers to optimize the patient’s management. Special risk
and benefit considerations are required upon diagnosis of
smaller asymptomatic lesions. This article’s focus is on
intracranial meningiomas (98 % of all meningiomas) which
in up to 60 % are located in parasagittal regions, in the
convexity, at the tuberculum sellae, and sphenoid ridge.
Less common locations comprise the olfactory groove, falx,
lateral ventricle, tentorium, middle fossa, and orbita [6].
Histopathology, Molecular Genetics
Meningioma cells arise from the arachnoid cap cells which
form the outer layer of the arachnoid mater. According to
the World Health Organization (WHO) [7] meningiomas are
categorized into 3 grades. Criteria include cell type, mitotic
activity, cellularity, necrosis, and brain invasion. Benign
meningiomas (WHO grade I) represent approximately
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90 % of all meningiomas and show several histologic var-
iants: meningothelial, fibrous (fibroblastic), transitional
(mixed), psammomatous, angiomatous, microcystic, secre-
tory, lymphoplasmacyte-rich, metaplastic meningioma.
They lack criteria of atypical or anaplastic meningioma.
Atypical meningiomas (WHO grade II) represent approxi-
mately 5 %–7 % of all meningiomas and comprise clear-cell
or chordoid variants. They show a mitotic index of ≥ 4
mitoses per 10 high-power fields (HPF), increased cellular-
ity, a high nucleus: cytoplasma ratio (‘small cells’), sheet-
like growth, and foci of spontaneous necrosis which are not
induced by embolization or radiation therapy. Even in the
absence of the cellular criteria of WHO grade II also brain
invasion (Fig. 1) qualifies for WHO grade II because of
recurrence and mortality rates similar to atypical meningio-
mas. Anaplastic meningiomas (WHO grade III, 3 % of all
meningiomas) include papillary and rhabdoid variants, and
show a mitotic index of ≥20 mitoses per 10 HPF and larger
zones of spontaneous necrosis. On microscopy they can
resemble carcinoma, sarcoma, or melanoma. Immunohisto-
chemistry eg, with staining against vimentin or epithelial
membrane antigen may assist in the differentiation of me-
ningioma from these tumors [8].
Meningiomas can originate spontaneously or be part of
hereditary syndromes such as neurofibromatosis type 2
(NF2), Li-Fraumeni, Turcot, Gardener, von Hippel-Lindau,
Cowden, Gorlin, and multiple endocrine neoplasia type I
[9]. For most of these syndromes the exact genetic relation-
ship to meningiomas has not been unraveled yet. The most
frequent genetic abnormality in meningiomas is genetic loss
of chromosome 22.q12.2. This chromosome band harbors
the NF2 gene. Its product, the Merlin protein, is considered
to participate in the regulation of cell-to-cell contact and
motility [10]. The majority of NF2-associated meningiomas
and approximately one half of sporadic meningiomas show
mutations of the NF2 gene. As the frequency of NF2 muta-
tions is similar in meningiomas of WHO grade I-III this
suggests that NF2 is rather involved in meningiomas initia-
tion than in progression. Meningioma progression is asso-
ciated with a plethora of molecular and genetic alterations
(eg, loss of tumor suppressor genes, hypermethylation of
CpG island) as well as changes of signal transduction. The
latter includes cell membrane receptors such as sex hormone
and somatostatin receptors. Within autocrine loops several
growth factors and their receptors are expressed, eg, epider-
mal growth factor (EGFR), EGF-like domain-containing
protein 6 (EGFL6) [11], platelet derived growth factor
(PDGFR), insulin-like growth factor II (IGF-II), transform-
ing growth factor-α (TGF-α, which binds to EGFR) [12].
Among intracellular signaling pathways the activation of
PI3K/Akt proteins reflects poor clinical course and brain
invasion. Mutations in the hedgehog transmembrane recep-
tor and activation of Notch receptors results in meningioma
development and chromosomal instability. The role of all
these factors (ie, whether they contribute to progression or
represent secondary events) is yet unclear [12, 13].
Prognostic Factors
The term ‘prognostic factor’ is differently used across the
literature on meningiomas and includes the ‘risk’ for inci-
dence and events such as tumor development eg, due to
radiation exposure as well as the risk for recurrence. The
latter depends on factors associated with the individual
tumor presentation (genetics, tumor grade) and with treat-
ment modalities. Most studies present data on prognostic
factors which show significant correlation with the WHO
tumor grade. Only a few studies have addressed the vari-
ability of the clinical course or treatment response eg, within
a given tumor grade. Identification of such factors would
allow stratifying patients into distinct molecular or biochem-
ical subgroups with particular regard to post-operative ther-
apy response.
Meningiomas which present with brain or bone invasion
show poorer outcomes compared with noninvading tumors
[14]. Also the status of sex hormone receptors impacts
prognosis: whereas meningiomas with progesterone recep-
tors show median recurrence rates of 5 %, meningiomas
with estrogen receptors or tumors lacking sex hormone
receptors present with recurrence rates of up to 30 % [15].
However, the extent of resection as classified by Simp-
son [16] and the WHO tumor grade [7] are among the
most strong prognostic factors. Relapse rates in WHO
grade I/II/III of 7 %/40 %/80 % have been reported, and
median survival in these studies was >10/11.5/2.7 years,
respectively [17, 18]. Although many patients with com-
pletely resected grade I meningiomas can be considered
Fig. 1 Newly diagnosed
meningioma. a–c, Axial
gadolinium enhanced MRI
showing dural tail (a), invasion
of brain (b), invasion of bone
(c). d, Axial CT corresponding
to (c).
337, Page 2 of 8 Curr Neurol Neurosci Rep (2013) 13:337
as cured, late recurrences are observed even after 20 years
(11 %–56 %) [19].
The risk for ‘early’ recurrence within WHO grade I
meningiomas was studied by investigating the expression
of the osteopontin protein [20•]. This integrin-binding pro-
tein is involved in proliferation, adhesion, migration, and
angiogenesis. In a series of 32 operated patients with WHO
grade I meningiomas 28 % recurrences were observed at a
mean follow up of 34 months. In patients with ‘early’
recurrences the osteopontin staining score from immunohis-
tochemistry was approximately 6 times higher compared
with nonrecurring tumors [20•]. This type of study signifies
the importance to assess the biological variability within
distinct histologic subgroups. Results may prompt prospec-
tive trials which address the role eg, of antiangiogenic
treatment in osteopontin positive meningioma.
Diagnosis
As with other brain tumors the clinical signs of meningio-
mas relate to their location. Personality changes, neuropsy-
chological deficits, sensory-motor, or visual symptoms,
aphasia as well as seizures frequently occur. Skull base
meningiomas present with cranial nerve dysfunction in the
majority of cases. Depending on location and size hydro-
cephalus may evolve. Computed tomography (CT) and
magnetic resonance imaging (MRI) are the tools to suspect
meningioma as described below. Despite the fact that MRI
has advantages over CT in assessing soft tissue character-
istics, the combination with CT gives additional information
regarding bone infiltration and therefore allows optimization
of surgery and radiation therapy planning [21, 22].
MRI
The characteristic signal alterations in T1- and T2- weighted
MRI together with anatomical extension towards adjacent
structures aids to confine the differentiation from other
tumors and nonmalignant lesions [23]. Due to the absence
of a blood–brain barrier meningiomas usually exhibit strong
enhancement of contrast medium on CT and T1-weighted
MRI (Fig. 1). The extent of brain edema is well illustrated in
T2-weighted and FLAIR MRI, and is thought to be partic-
ularly extensive in WHO grade I meningiomas [24, 25].
MRI can depict arachnoid layer to predict brain adhesion
and facilitates to plan the surgical dissection of tumor from
brain tissue. Since the prognosis highly correlates with the
extent of resection of infiltrated dura, pathologic changes of
the dura can be interpreted by evaluating the dural tail sign
on MRI (Fig. 1a). This information helps to choose the
correct size of craniotomy to achieve the maximal distance
of 2.5 cm from the tumor base in convexity meningiomas
[26]. Diffusion tensor imaging (DTI) helps in preoperative
identification of displaced fibers, which is particularly help-
ful in planning surgical access to intraventricular meningio-
mas [27]. Assessment of tumor growth which may aid in
treatment decisions was, so far, mainly based on the mea-
surement of cross sectional tumor diameters. With the ad-
vance of automated volumetric and 3D reconstruction
analysis a superior tool is provided for early detection of
tumor growth [28].
CT
CT provides information on hyperostosis, bone destruc-
tion, and infiltration which is of utmost importance for
planning surgical and radiation strategies [22, 29]. CT
also detects tumor calcification, which is a hint for slow
tumor growth particularly in elderly patients [3, 30]. In
addition, CT aids to clarify the spatial relationship be-
tween skull base tumors, paranasal sinuses, and pneuma-
tization of the anterior clinoid process.
Cerebral Angiography (CAG)
Most meningiomas harbor a very dense vascularization,
which in case of large tumors carries the risk of intense
intraoperative bleeding. Preoperative embolization can re-
duce surgical morbidity in selected cases [31]. Embolization
might rarely be applied prior to radiation or as standalone
therapy. Careful interdisciplinary decision making is re-
quired before the indication of embolization is made, since
risks of embolization such as hemorrhage, extensive edema
formation, or vascular infarctions can have negative impact
on functional outcome [32]. CAG also unravels the degree
of proximity between skull-base meningiomas and vascular
structures with exact depiction of stenosis, occlusion, and
incidental aneurysms. Vessel wall irregularities on CAG are
a more sensitive hint to tumor-invasion into the vessel wall
compared with MRI.
SPECT and PET
Single Photon Emission Computed Tomography (SPECT)
and Positron Emission Tomography (PET) provide informa-
tion about cellular processes and biological characteristics
of tumors. In meningiomas the clinically most relevant issue
is the search for the presence of somatostatin receptors
(SSR) [33]. The presence of SSR favors the diagnosis of
meningioma in a patient not amenable for surgery. It aids in
the target volume delineation for radiation therapy planning
[34], and in the differentiation between residual or recurrent
tumor from scar tissue [35]. The presence of SSR also
allows targeted therapy with receptor binding ligands (see
below). However, future well-designed clinical studies are
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warranted to demonstrate the feasibility and value of PET
for clinical routine.
Ongoing research in all imaging modalities is focusing on
the prediction of histologic grade and improving differential
diagnosis, eg, dural metastasis, hemangiopericytoma vs me-
ningioma. So far none of these modalities are reliable enough
to substitute the histopathologic analysis of tumor tissue.
Treatment
Despite the lack of class I evidence based guidelines, correct
decision making in patients with newly diagnosed intracranial
mass suspicious for meningioma is crucial for achieving opti-
mal clinical outcome and patient survival [36, 37]. Complete
tumor resection is associated with the longest progression-free
and overall survival, and Simpson grade I resection should
continue to be the goal for convexity meningiomas [16].
However, total resection cannot be achieved in more than
50 % of newly diagnosed meningiomas. Therefore partial
tumor removal followed by observation, radiation therapy, or
in rare cases, systemic chemotherapy has to be discussed in an
interdisciplinary approach. Based on the natural history
patients younger than 60 to 70 years of age and those with
meningiomas characterized by surrounding brain hyperinten-
sity on T2-weighted MRI (edema), absence of calcification,
and tumor diameter > 25–30 mm exhibit a higher risk for early
recurrence [3, 17, 30, 38]. Special awareness of detecting
genetic disorders is crucial to respect the course of natural
history and act accordingly, especially in patients with NF2
associated tumors which frequently demonstrate a saltatory
growth pattern [39]. Because new tumors can develop in
NF2 patients over their lifetime and because radiographic and
symptomatic progression are unpredictable, resection may be
best reserved for symptom-producing tumors, de novo, and
brain edema-associated meningiomas in NF2 patients [39, 40].
Surgery
Indications for surgery in general include symptomatic tumors
with the option for total resection, subtotal resection followed
by radiation therapy of remnants, or growth of asymptomatic
tumors on serial images. Surgical risks have to be discussed
with the patient, and the patient’s preference has to be
respected based on this discussion [41, 42]. Surgical strategies
have significantly improved outcomes within the past 30 years
[17, 43•]. The introduction of the surgical microscope in neu-
rosurgery was a major step in improving safety with extension
of surgical tumor removal [44]. Additional technological prog-
ress enhanced surgical safety and extent of resection in the past
years. This includes tools such as neuro-navigation [17], intra-
operative electrophysiology, indocyanine angiography [45], 5-
ALA [46, 47], intraoperative MRI [48], and intraoperative
sonography [49]. With the adoption of these utilities Simpson
grade I resection is achieved in the majority of convexity
meningiomas with minimal morbidity [17]. In case of tumor-
invasion into to skull, bone removal and intraoperative molded
cranioplasty [29, 50] has to be considered to prevent tumor
recurrence originating from skull.
Endoscopy
Advanced knowledge in the endoscopic anatomy of the skull
base delivered new surgical corridors to minimize morbidity
related to the surgical access and cosmetic issues. However,
compared with traditional craniotomies, the major limitation
of the endoscopic approach is the restricted surgical corridor,
challenging cranial base repair, and limited hemostasis in
hypervascularized tumors. Over the same period of time,
new open surgical trans-cranial approaches have challenged
the traditional operative corridors to the anterior skull base.
Neither of the techniques exclude each other and the future
direction will be a combined approach to provide the benefits
of all techniques and to maximize resection with minimized
morbidity and mortality [17, 51–54].
Radiation Therapy
Radiation therapy (RT) evolved as a standard in the treatment
of meningiomas. Indications for RT depend on tumor size,
stage of disease, WHO grade, and include residual or non-
resectable meningioma at the time of first diagnosis, recurrent
or progressive nonresectable meningioma, and meningioma of
WHO grade II and III. The RT modalities comprise fraction-
ated external beam radiation, stereotactic radiosurgery, and
particle therapy (mainly proton therapy). Stereotactic radio-
surgery harbors a growing list of names depending of the
manufacturer’s naming (eg, linear accelerator (Linac), Cyber-
Knife® (Accuray Inc., Sunnyvale, CA, USA), Gamma Knife®
(Elekta Instruments, Stockholm, Sweden), Novalis® (Brain-
LAB, Heimstetten, Germany) etc..). In large tumors the side
effects and limited tumor control outweigh the benefits of RT
compared with surgery [55]. Complications of RT include alo-
pecia, tooth loss, new onset of seizures, neurologic deficits,
cranial nerve palsy, headache, edema, and radio-necrosis or
delayed hydrocephalus. On the other hand tumor control rates
for stereotactic radiosurgery are equivalent to sub-total resection
with lower morbidity than surgery of skull base tumors [56, 57].
The goals of RT are prolongation of progression-free
survival with preservation of neurologic function. Complete
tumor eradication is not possible with RT modalities to date,
however, partial tumor shrinkage has been observed in
different series [58–60]. The assessment of RT effects is in
general difficult because of the different RT modalities used
in meningioma treatment and limited data of randomized
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trials in comparison with surgery [61]. Future studies are
required to elaborate the optimal radiation dosage and to
prevent treatment failures [62, 63].
RT has to be considered as an alternative to surgery in
elderly patients with high surgical risk. One of the largest
series with gamma knife treatment of benign meningiomas
(5300 treated tumors) reported on 5- and 10-year progression-
free survival rates of 95.2 % and 88.6 %, respectively [64••].
Systemic Therapy
Systemic treatment has been administered as either cytotox-
ic or as targeted therapy. As both strategies are not consid-
ered standard treatment at the time of first diagnosis they
have been given in patients with advanced or nonresectable
tumors, which in many cases were heavily pretreated with
various courses of surgery and radiation therapy. This led to
reports on noncontrolled case studies which included small
numbers of patients, and patients with various WHO grades
and stages of disease. Examples are presented in the Table 1.
Targeted therapies aim at the inhibition of hormonal
receptors, angiogenesis, or growth factor signaling. Overall,
at best modest responses were observed yet. Somatostatin
receptors (SSR) in meningiomas are of particular interest as
they can be visualized with SPECT and PET [65]. SSR are
present in up to 70 % of meningiomas [66]. They are catego-
rized into 5 subtypes, where subtype 2A (sst2A) is involved in
direct (eg, cytostatic, apoptosis) and indirect (eg, antiangio-
genic) effects [67]. Octreotide and pasireotide represent syn-
thetic SSR ligands which modify the receptor activity.
Pasireotide exhibits higher sst2A affinity (1.0 nmol/L) com-
pared with octreotide (0.4) and somatostatin itself (0.2) [68].
With regard to treatment the visualization of SSR using PET
has 2 major applications: (1) the PET radiotracer (eg, 68Ga-
DOTATOC) uptake allows delineation of the tumor volume for
radiation therapy planning [34]; (2) the noninvasive detection
of SSR particularly in nonoperated progressive or recurrent
tumors allows meningioma treatment with either the nonradio-
active labeled somatostatin (sandostatin LAR), or with
octreotide charged with the therapeutic nuclide Yttrium-90
[69] or Lutetium-177 [70•] (Table 1). Two studies using
paseotride are posted on www.clinicaltrials.gov. They are
denoted as active but not recruiting (NCT00859040,
NCT00813592, accessed January 2013).
Conclusions
Long-term tumor control or even cure can be achieved in
many WHO I meningiomas with modern surgical and radio-
therapy techniques. In the elderly asymptomatic meningiomas
Table 1 Systemic therapies in meningioma patients
Therapy Ref. Number of patients
(WHO I/II/III)
Results
Hydroxyurea [71] 20 (16/3/1) 1 patient with minor response; 93 % PFS-12 in WHO I;
progression within 3 to 10 months in WHO II and III
Hydroxyurea [72] 35 (0/22/13) no radiographic response; 3 % PFS-6; PFS 2 months
Temozolomide [73] 16 (16/0/0) no radiographic response; TTP 5 months; OS 7.5 months
Estrogen receptor; tamoxifen [74] 19 (not reported) 3 patients with minor responses (CT or MRI), 6 patients stable
for 31 months, TTP 15.1 months
Progesteron receptor; mifepristone [75] 28 (*) minor responses in 8 patients (men, premenopausal women)
SSR; octreotide [76] 16 (8/3/5) 31 % partial response, 31 % stable disease; TTP 5 months
SSR; octreotide [77] 11 (4/2/5) no radiographic response; TTP 17 weeks; OS 2.7 years
SSR; 90Y-DOTATOC [69] 29 (14/9/6) 33 % stable disease at 12 months; TTP WHO I 61 months, TTP
WHO II,III 13 months
SSR; 177Lu-DOTATOC, -DOTATATE
immediately followed by radiation therapy
[70] 9 (7/2/0) each 1 patient with complete and partial remission; other
patients stable at median follow-up of 13.4 months
VEGF [78] 15 (0/6/9) 43.8 % PFS-6; PFS 26 weeks
VEGF alone or plus etoposide [79] 13 (5/5/3) 1 partial response, 11 stable disease; PFS 15.8 months
PDGF-R; imatinib [80] 9 (1/2/6) 66.7 % PFS-6; OS 16 months
EGFR; gefitinib; erlotinib [81] 25 (8/9/8) 32 % stable disease; 13 % PFS-12 and 50 % OS-12 in WHO I;
18 % PFS-12 and 65 % OS-12 in WHO II and III
EGFR epidermal growth factor receptor, PDGF-R platelet derived growth factor receptor, PFS, OS, median progression-free or overall survival,
PFS-6, PFS-12, OS-6, OS-12, percentage of patients free of progression or alive at 6 and 12 months, SSR somatostatin receptor, TTPmedian time to
progression, VEGF vascular endothelial growth factor
*22 benign, 2 malignant meningioma, 4 patients without biopsy
Curr Neurol Neurosci Rep (2013) 13:337 Page 5 of 8, 337
(‘incidentalomas’) can be managed with a wait-and-see strat-
egy without surgery. Meningiomas WHO I not amenable to
total resection, and meningiomas of grade II and III represent
the major therapeutic challenges. Whereas surgery and radio-
therapy are well established at the time of tumor diagnosis and
recurrence the role for systemic therapies remains unclear.
Several reasons account for the latter: (1) systemic therapies
have been largely administered to patients which were heavily
pretreated by surgery and radiotherapy; (2) most reports are
based upon retrospective, heterogeneous, and small patient
series and included meningiomas with various tumor grades;
(3) molecular markers or prognostic factors linked to tumor
behavior were not used for stratification or randomization; (4)
response criteria are not available. Given the high frequency
of meningiomas prospective studies which implement these
issues are strongly requested and should be feasible.
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